Operating until
2011
Website
Business classification
VCID: 106781
Profile
Corporate information
Official name
Genzyme Corp
Registration country
Official name
Genzyme Corp
Registration country
Investment activity status
Not investing
Funding
Funding rounds
Acquisition USD 20,000,000,000
USD 20,000,000,000 (16 Feb 2011) at USD 20,000,000,000 valuation.
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Sanofi Aventis | USD 20,000,000,000 (USD 20,000,000,000). Initial investment. Round participant. |
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Kleiner Perkins Caufield & Byers LLC | Venture capital firm. | United States |
Cap Table
Current and past shareholders
| Investor | Contacts | Round | |
|---|---|---|---|
|
|
Kleiner Perkins Caufield & Byers LLC Venture capital firm. |
+1 (650) 233-2750 |
N/A |
|
|
Sanofi Aventis |
Acquisition |
Investments
Selected investments
| Company | Country | Date | Notes | ||
|---|---|---|---|---|---|
|
Bluebird Bio Inc Developer of an innovative gene therapies for severe genetic disorders |
United States | 1 Mar 2010 | Series B |
|
|
Fate Therapeutics Inc |
United States | 1 Nov 2009 | Series B Initial investment. Round participant. Active |
|
|
|
Sirtris Pharmaceuticals Inc |
United States | 1 Apr 2006 | Series C |
|
|
|
GelTex Pharmaceuticals |
United States | 11 Sep 2000 | Acquisition 1,000,000,000 (USD 1,000,000,000) deal size. |
|
|
|
ILEX Oncology Inc |
United States | N/A |